# Olatorepatide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/olatorepatide

> The next catalyst for olatorepatide, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is its topline data readout, Jan to Apr 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | olatorepatide |
| Codes | HS-20094 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Hidradenitis Suppurativa](https://sec-api.dev/indications/hidradenitis-suppurativa), [Overweight or Obesity](https://sec-api.dev/indications/overweight-or-obesity), [Overweight or Obesity Without Diabetes](https://sec-api.dev/indications/overweight-or-obesity-without-diabetes) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Overweight or Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07431086

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Overweight or Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07431086

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Overweight or Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07685808 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07685808

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Overweight or Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07685808 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07685808

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07830329 (Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07830329

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07830329 (Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07830329

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Overweight or Obesity Without Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07896265 (Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-12-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07896265

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Overweight or Obesity Without Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07896265 (Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-12-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07896265

## Same indication

- [Avtx-009 regimen 1](https://sec-api.dev/pdufa/avtx-009-regimen-1) (AVTX)
- [BRINSUPRI® (brensocatib)](https://sec-api.dev/pdufa/brensocatib) (INSM)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [SAR445399](https://sec-api.dev/pdufa/sar445399) (SNY)
- [Sonelokimab](https://sec-api.dev/pdufa/sonelokimab) (MLTX)
- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart) (MRK)
- [Zasocitinib (dose a)](https://sec-api.dev/pdufa/zasocitinib-dose-a) (TAK)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [January 2028](https://sec-api.dev/fda-calendar/2028-01), [November 2028](https://sec-api.dev/fda-calendar/2028-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/olatorepatide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Olatorepatide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/olatorepatide

```bibtex
@misc{secapidev_pdufa_olatorepatide_20261116,
  title        = {Olatorepatide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/olatorepatide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_olatorepatide_20261116","title":"Olatorepatide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/olatorepatide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
